The life expectancy of people with schizophrenia is approximately 15 years less than that of the general population, with cardiovascular disease being the major cause of premature death. Metabolic abnormalities including obesity, which are prevalent among people with schizophrenia, have been known to raise mortality risk due to cardiovascular disease, and could be target of interventions for extending life expectancy.
 To date, several studies including pharmacologic and non-pharmacologic interventions have been conducted for metabolic abnormalities among patients with schizophrenia. The aim of this narrative review is to elucidate the efficacy of pharmacologic and non-pharmacologic interventions for metabolic abnormalities.
 <Author's abstract>